TY - JOUR
T1 - Surveillance for control of antimicrobial resistance
AU - EPI-Net COMBACTE-MAGNET Group
AU - Tacconelli, Evelina
AU - Sifakis, Frangiscos
AU - Harbarth, Stephan
AU - Schrijver, Remco
AU - van Mourik, Maaike
AU - Voss, Andreas
AU - Sharland, Mike
AU - Rajendran, Nithya Babu
AU - Rodríguez-Baño, Jesús
AU - Bielicki, Julia
AU - de Kraker, Marlieke
AU - Gandra, Sumanth
AU - Gastmeier, Petra
AU - Gilchrist, Kim
AU - Gikas, Achilleas
AU - Gladstone, Beryl Primrose
AU - Goossens, Herman
AU - Jafri, Hasan
AU - Kahlmeter, Gunnar
AU - Leus, Frank
AU - Luxemburger, Christine
AU - Malhotra-Kumar, Surbhi
AU - Marasca, Giuseppe
AU - McCarthy, Michael
AU - Navarro, María Dolores
AU - Nuñez-Nuñez, María
AU - Oualim, Abdel
AU - Price, Jessica
AU - Robert, Jérôme
AU - Sommer, Harriet
AU - von Cube, Maja
AU - Vuong, Cuong
AU - Wiegand, Irith
AU - Witschi, Anne Therese
AU - Wolkewitz, Martin
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/3
Y1 - 2018/3
N2 - Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions, infection control policies, and antimicrobial development. In Europe, although the European Antimicrobial Resistance Surveillance Network provides annual reports on monitored resistant bacteria, national surveillance efforts are still fragmented and heterogeneous, and have substantial structural problems and issues with laboratory data. Most incidence and prevalence data cannot be linked with relevant epidemiological, clinical, or outcome data. Genetic typing, to establish whether trends of antimicrobial resistance are caused by spread of resistant strains or by transfer of resistance determinants among different strains and species, is not routinely done. Furthermore, laboratory-based surveillance using only clinical samples is not likely to be useful as an early warning system for emerging pathogens and resistance mechanisms. Insufficient coordination of surveillance systems of human antimicrobial resistance with animal surveillance systems is even more concerning. Because results from food surveillance are considered commercially sensitive, they are rarely released publicly by regulators. Inaccurate or incomplete surveillance data delay a translational approach to the threat of antimicrobial resistance and inhibit the identification of relevant target microorganisms and populations for research and the revitalisation of dormant drug-discovery programmes. High-quality, comprehensive, and real-time surveillance data are essential to reduce the burden of antimicrobial resistance. Improvement of national antimicrobial resistance surveillance systems and better alignment between human and veterinary surveillance systems in Europe must become a scientific and political priority, coordinated with international stakeholders within a global approach to reduce the burden of antimicrobial resistance.
AB - Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions, infection control policies, and antimicrobial development. In Europe, although the European Antimicrobial Resistance Surveillance Network provides annual reports on monitored resistant bacteria, national surveillance efforts are still fragmented and heterogeneous, and have substantial structural problems and issues with laboratory data. Most incidence and prevalence data cannot be linked with relevant epidemiological, clinical, or outcome data. Genetic typing, to establish whether trends of antimicrobial resistance are caused by spread of resistant strains or by transfer of resistance determinants among different strains and species, is not routinely done. Furthermore, laboratory-based surveillance using only clinical samples is not likely to be useful as an early warning system for emerging pathogens and resistance mechanisms. Insufficient coordination of surveillance systems of human antimicrobial resistance with animal surveillance systems is even more concerning. Because results from food surveillance are considered commercially sensitive, they are rarely released publicly by regulators. Inaccurate or incomplete surveillance data delay a translational approach to the threat of antimicrobial resistance and inhibit the identification of relevant target microorganisms and populations for research and the revitalisation of dormant drug-discovery programmes. High-quality, comprehensive, and real-time surveillance data are essential to reduce the burden of antimicrobial resistance. Improvement of national antimicrobial resistance surveillance systems and better alignment between human and veterinary surveillance systems in Europe must become a scientific and political priority, coordinated with international stakeholders within a global approach to reduce the burden of antimicrobial resistance.
UR - http://www.scopus.com/inward/record.url?scp=85032574276&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(17)30485-1
DO - 10.1016/S1473-3099(17)30485-1
M3 - Review article
C2 - 29102325
AN - SCOPUS:85032574276
VL - 18
SP - e99-e106
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
SN - 1473-3099
IS - 3
ER -